JP2008540636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540636A5 JP2008540636A5 JP2008511822A JP2008511822A JP2008540636A5 JP 2008540636 A5 JP2008540636 A5 JP 2008540636A5 JP 2008511822 A JP2008511822 A JP 2008511822A JP 2008511822 A JP2008511822 A JP 2008511822A JP 2008540636 A5 JP2008540636 A5 JP 2008540636A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkynyl
- alkenyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 442
- 125000001072 heteroaryl group Chemical group 0.000 claims 68
- 125000003118 aryl group Chemical group 0.000 claims 65
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 55
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 46
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 13
- -1 hydroxy, amino Chemical group 0.000 claims 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 208000015114 central nervous system disease Diseases 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- SWHNJBQXOVENNO-ZDUSSCGKSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=C1 SWHNJBQXOVENNO-ZDUSSCGKSA-N 0.000 claims 2
- MUMITROLTOTPRS-UHFFFAOYSA-N [3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 MUMITROLTOTPRS-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- YGFKQMZFNSYHSJ-AWEZNQCLSA-N (2-fluorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 YGFKQMZFNSYHSJ-AWEZNQCLSA-N 0.000 claims 1
- CUYJJKPKGPPPQQ-AWEZNQCLSA-N (2-fluoropyridin-4-yl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=CC=CC=3)N=2)=C1 CUYJJKPKGPPPQQ-AWEZNQCLSA-N 0.000 claims 1
- QILNICGVSWRKQG-HNNXBMFYSA-N (2-methoxyphenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound COC1=CC=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 QILNICGVSWRKQG-HNNXBMFYSA-N 0.000 claims 1
- OJTKLAQTJVFVGM-INIZCTEOSA-N (2-methylphenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound CC1=CC=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 OJTKLAQTJVFVGM-INIZCTEOSA-N 0.000 claims 1
- HUESLABJPSSCHZ-AWEZNQCLSA-N (3,4-dichlorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 HUESLABJPSSCHZ-AWEZNQCLSA-N 0.000 claims 1
- CYINQQLYAWDDKD-ZDUSSCGKSA-N (3,4-dichlorophenyl)-[(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1 CYINQQLYAWDDKD-ZDUSSCGKSA-N 0.000 claims 1
- HDOANYBDYVEKAB-HNNXBMFYSA-N (3,4-difluorophenyl)-[(3s)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NOC([C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=N1 HDOANYBDYVEKAB-HNNXBMFYSA-N 0.000 claims 1
- DHKSPUYDGMLYJN-HNNXBMFYSA-N (3,4-difluorophenyl)-[(3s)-3-[5-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NC([C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=NO1 DHKSPUYDGMLYJN-HNNXBMFYSA-N 0.000 claims 1
- MFLBEOMDTVVFJP-ZDUSSCGKSA-N (3,5-difluorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound FC1=CC(F)=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=CC=CC=3)N=2)=C1 MFLBEOMDTVVFJP-ZDUSSCGKSA-N 0.000 claims 1
- JEVNODHCJYDLEJ-LBPRGKRZSA-N (3,5-difluorophenyl)-[(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)C=C(F)C=2)=C1 JEVNODHCJYDLEJ-LBPRGKRZSA-N 0.000 claims 1
- BRCGTQYXPAHSFZ-AWEZNQCLSA-N (3,5-dimethyl-1,2-oxazol-4-yl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound CC1=NOC(C)=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 BRCGTQYXPAHSFZ-AWEZNQCLSA-N 0.000 claims 1
- HXKDWRIMAXXTHR-HNNXBMFYSA-N (3-fluorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=CC=CC=3)N=2)=C1 HXKDWRIMAXXTHR-HNNXBMFYSA-N 0.000 claims 1
- IIQHTWCSAKKDOP-HNNXBMFYSA-N (4-chlorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 IIQHTWCSAKKDOP-HNNXBMFYSA-N 0.000 claims 1
- QVBBSMSTRBNOMJ-AWEZNQCLSA-N (4-chlorophenyl)-[(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(Cl)=CC=2)=C1 QVBBSMSTRBNOMJ-AWEZNQCLSA-N 0.000 claims 1
- XLSSJGKIWYBMNQ-HNNXBMFYSA-N (4-fluorophenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 XLSSJGKIWYBMNQ-HNNXBMFYSA-N 0.000 claims 1
- AYLPWTUONGSDQN-HNNXBMFYSA-N (4-fluorophenyl)-[(3s)-3-(3-phenylsulfanyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(SC=3C=CC=CC=3)N=2)CCC1 AYLPWTUONGSDQN-HNNXBMFYSA-N 0.000 claims 1
- WTOGNIYSSZSJPM-INIZCTEOSA-N (4-fluorophenyl)-[(3s)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NOC([C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=N1 WTOGNIYSSZSJPM-INIZCTEOSA-N 0.000 claims 1
- BPRBGPALOJVLPF-SFHVURJKSA-N (4-fluorophenyl)-[(3s)-3-[5-(2-phenylethyl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(CCC=3C=CC=CC=3)ON=2)CCC1 BPRBGPALOJVLPF-SFHVURJKSA-N 0.000 claims 1
- OGLUZYAARIAUIK-QAPCUYQASA-N (4-fluorophenyl)-[(3s)-3-[5-[(1r)-1-phenylethyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C([C@@H](C1)C=2N=C(ON=2)[C@H](C)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(F)C=C1 OGLUZYAARIAUIK-QAPCUYQASA-N 0.000 claims 1
- OGLUZYAARIAUIK-YJBOKZPZSA-N (4-fluorophenyl)-[(3s)-3-[5-[(1s)-1-phenylethyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C([C@@H](C1)C=2N=C(ON=2)[C@@H](C)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(F)C=C1 OGLUZYAARIAUIK-YJBOKZPZSA-N 0.000 claims 1
- XNZSOPFYWVTZAN-INIZCTEOSA-N (4-fluorophenyl)-[(3s)-3-[5-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NC([C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=NO1 XNZSOPFYWVTZAN-INIZCTEOSA-N 0.000 claims 1
- YFRJRGVGLXIGMN-INIZCTEOSA-N (4-fluorophenyl)-[(3s)-3-[5-[(4-fluorophenyl)methylamino]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CNC1=NC([C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=NO1 YFRJRGVGLXIGMN-INIZCTEOSA-N 0.000 claims 1
- AHHDFYLXGGNZPQ-FUHWJXTLSA-N (4-fluorophenyl)-[(3s)-3-[5-[(r)-hydroxy(phenyl)methyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C([C@@H](C1)C=2N=C(ON=2)[C@H](O)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(F)C=C1 AHHDFYLXGGNZPQ-FUHWJXTLSA-N 0.000 claims 1
- AHHDFYLXGGNZPQ-WMZOPIPTSA-N (4-fluorophenyl)-[(3s)-3-[5-[(s)-hydroxy(phenyl)methyl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C([C@@H](C1)C=2N=C(ON=2)[C@@H](O)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(F)C=C1 AHHDFYLXGGNZPQ-WMZOPIPTSA-N 0.000 claims 1
- XLSSJGKIWYBMNQ-UHFFFAOYSA-N (4-fluorophenyl)-[3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 XLSSJGKIWYBMNQ-UHFFFAOYSA-N 0.000 claims 1
- XGDOXAKRWQEBFM-INIZCTEOSA-N (4-methoxyphenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 XGDOXAKRWQEBFM-INIZCTEOSA-N 0.000 claims 1
- RFSWMYADYIKSGY-KRWDZBQOSA-N (4-methylphenyl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 RFSWMYADYIKSGY-KRWDZBQOSA-N 0.000 claims 1
- MSRNRQDUNRTTKH-ZDUSSCGKSA-N (5-methyl-1,2-oxazol-4-yl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=CC=CC=3)N=2)=C1C MSRNRQDUNRTTKH-ZDUSSCGKSA-N 0.000 claims 1
- DLHCRKQPDNCDPF-AWEZNQCLSA-N (6-fluoropyridin-3-yl)-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=CC=CC=3)N=2)CCC1 DLHCRKQPDNCDPF-AWEZNQCLSA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- ARUANAONZLTXPS-LBPRGKRZSA-N 1h-imidazol-5-yl-[(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]methanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2NC=NC=2)=NC=1OC1=CC=CC=C1 ARUANAONZLTXPS-LBPRGKRZSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102100022197 Glutamate receptor ionotropic, kainate 1 Human genes 0.000 claims 1
- 101710112359 Glutamate receptor ionotropic, kainate 1 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- IDRSRZPBOJJRRM-LBPRGKRZSA-N [(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-(1,3-thiazol-5-yl)methanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2SC=NC=2)=NC=1OC1=CC=CC=C1 IDRSRZPBOJJRRM-LBPRGKRZSA-N 0.000 claims 1
- KKOQSEWPKNKOPH-INIZCTEOSA-N [(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-phenylmethanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2C=CC=CC=2)=NC=1OC1=CC=CC=C1 KKOQSEWPKNKOPH-INIZCTEOSA-N 0.000 claims 1
- JXAOCMLXKNTYGF-AWEZNQCLSA-N [(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-pyridin-2-ylmethanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2N=CC=CC=2)=NC=1OC1=CC=CC=C1 JXAOCMLXKNTYGF-AWEZNQCLSA-N 0.000 claims 1
- TTWUZLGUPRULHM-HNNXBMFYSA-N [(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-pyridin-3-ylmethanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2C=NC=CC=2)=NC=1OC1=CC=CC=C1 TTWUZLGUPRULHM-HNNXBMFYSA-N 0.000 claims 1
- YXVVMNIPTAKMPW-HNNXBMFYSA-N [(3s)-3-(3-phenoxy-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-pyridin-4-ylmethanone Chemical compound N=1OC([C@H]2CCCN(C2)C(=O)C=2C=CN=CC=2)=NC=1OC1=CC=CC=C1 YXVVMNIPTAKMPW-HNNXBMFYSA-N 0.000 claims 1
- NHISSLTUUYENPE-HNNXBMFYSA-N [(3s)-3-(5-anilino-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(NC=3C=CC=CC=3)ON=2)CCC1 NHISSLTUUYENPE-HNNXBMFYSA-N 0.000 claims 1
- CYMNQIDOMSOBDX-KRWDZBQOSA-N [(3s)-3-(5-benzyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(CC=3C=CC=CC=3)ON=2)CCC1 CYMNQIDOMSOBDX-KRWDZBQOSA-N 0.000 claims 1
- WHRRFSUWGFUWOA-SFHVURJKSA-N [(3s)-3-(5-benzyltetrazol-2-yl)piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](N2N=C(CC=3C=CC=CC=3)N=N2)CCC1 WHRRFSUWGFUWOA-SFHVURJKSA-N 0.000 claims 1
- XIQIJMBTDBAKDW-ZDUSSCGKSA-N [(3s)-3-[3-(2-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C(=CC=CC=3)F)N=2)CCC1 XIQIJMBTDBAKDW-ZDUSSCGKSA-N 0.000 claims 1
- QAFHZDFLCGZAOY-NSHDSACASA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(1,3-thiazol-5-yl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2SC=NC=2)=C1 QAFHZDFLCGZAOY-NSHDSACASA-N 0.000 claims 1
- YWFTXCFWFJBRRB-NSHDSACASA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(1h-imidazol-5-yl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2NC=NC=2)=C1 YWFTXCFWFJBRRB-NSHDSACASA-N 0.000 claims 1
- RUFSWXIRYCMPCC-ZDUSSCGKSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C(=CC=CC=2)F)=C1 RUFSWXIRYCMPCC-ZDUSSCGKSA-N 0.000 claims 1
- FDJAEJHJNRLZRP-ZDUSSCGKSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(2-fluoropyridin-4-yl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)N=CC=2)=C1 FDJAEJHJNRLZRP-ZDUSSCGKSA-N 0.000 claims 1
- MIHNSROGCHBPKM-AWEZNQCLSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 MIHNSROGCHBPKM-AWEZNQCLSA-N 0.000 claims 1
- COQZGNWPYBVDCQ-HNNXBMFYSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 COQZGNWPYBVDCQ-HNNXBMFYSA-N 0.000 claims 1
- PWEZDXFTPKFAAL-AWEZNQCLSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)C=CC=2)=C1 PWEZDXFTPKFAAL-AWEZNQCLSA-N 0.000 claims 1
- QSZZFAUQERYTIY-HNNXBMFYSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=C(F)C=CC=3)N=2)=C1 QSZZFAUQERYTIY-HNNXBMFYSA-N 0.000 claims 1
- MUMITROLTOTPRS-AWEZNQCLSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 MUMITROLTOTPRS-AWEZNQCLSA-N 0.000 claims 1
- KBTHKZSHURSRDH-HNNXBMFYSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 KBTHKZSHURSRDH-HNNXBMFYSA-N 0.000 claims 1
- XBMADWHQLVGPCT-INIZCTEOSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C[C@@H](C=2ON=C(OC=3C=C(F)C=CC=3)N=2)CCC1 XBMADWHQLVGPCT-INIZCTEOSA-N 0.000 claims 1
- DCRWSOSZOXMGMA-LBPRGKRZSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(OC=3C=C(F)C=CC=3)N=2)=C1C DCRWSOSZOXMGMA-LBPRGKRZSA-N 0.000 claims 1
- FYRAPCJCFKKLPE-HNNXBMFYSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC=CC=2)=C1 FYRAPCJCFKKLPE-HNNXBMFYSA-N 0.000 claims 1
- ADEUSGVBSVCVAK-ZDUSSCGKSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-pyridin-2-ylmethanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2N=CC=CC=2)=C1 ADEUSGVBSVCVAK-ZDUSSCGKSA-N 0.000 claims 1
- UDBXTSHYJBLXDW-AWEZNQCLSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-pyridin-3-ylmethanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC=CC=2)=C1 UDBXTSHYJBLXDW-AWEZNQCLSA-N 0.000 claims 1
- JSXKYYCJNJPGCZ-AWEZNQCLSA-N [(3s)-3-[3-(3-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-pyridin-4-ylmethanone Chemical compound FC1=CC=CC(OC=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=CN=CC=2)=C1 JSXKYYCJNJPGCZ-AWEZNQCLSA-N 0.000 claims 1
- CZUMPSXIWUNCLN-UHFFFAOYSA-N [3-[3-(4-fluorophenoxy)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1OC1=NOC(C2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=N1 CZUMPSXIWUNCLN-UHFFFAOYSA-N 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000003227 neuromodulating effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0510139.9A GB0510139D0 (en) | 2005-05-18 | 2005-05-18 | Novel compounds B1 |
| PCT/IB2006/001882 WO2006129199A1 (en) | 2005-05-18 | 2006-05-17 | Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540636A JP2008540636A (ja) | 2008-11-20 |
| JP2008540636A5 true JP2008540636A5 (enExample) | 2009-07-02 |
Family
ID=34708377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511822A Pending JP2008540636A (ja) | 2005-05-18 | 2006-05-17 | 代謝型グルタミン酸受容体の陽性アロステリック調節因子としての新規複素環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100004284A1 (enExample) |
| EP (1) | EP1896464A1 (enExample) |
| JP (1) | JP2008540636A (enExample) |
| KR (1) | KR20080017040A (enExample) |
| CN (1) | CN101218231B (enExample) |
| AU (1) | AU2006253863A1 (enExample) |
| BR (1) | BRPI0610067A2 (enExample) |
| CA (1) | CA2609513A1 (enExample) |
| EA (1) | EA014904B1 (enExample) |
| GB (1) | GB0510139D0 (enExample) |
| IL (1) | IL187189A0 (enExample) |
| MX (1) | MX2007014400A (enExample) |
| NO (1) | NO20076477L (enExample) |
| NZ (1) | NZ564255A (enExample) |
| UA (1) | UA92914C2 (enExample) |
| WO (1) | WO2006129199A1 (enExample) |
| ZA (1) | ZA200710280B (enExample) |
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006123255A2 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| GEP20125425B (en) | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP5330260B2 (ja) | 2006-12-06 | 2013-10-30 | スミスクライン ビーチャム コーポレーション | 二環式化合物ならびに抗糖尿病薬としての使用 |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| JP4891111B2 (ja) * | 2007-02-16 | 2012-03-07 | 富士フイルム株式会社 | ズームレンズ |
| US8338142B2 (en) * | 2007-02-19 | 2012-12-25 | Kaneka Corporation | Method for producing optically active 3-aminopiperidine or salt thereof |
| CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| EP2259777A2 (en) * | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| JP5683489B2 (ja) | 2009-01-12 | 2015-03-11 | アレイ バイオファーマ、インコーポレイテッド | ピペリジン含有化合物およびその用途 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| NZ594064A (en) | 2009-01-30 | 2012-08-31 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| WO2010124055A1 (en) * | 2009-04-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | 2-alkyl piperidine mglur5 receptor modulators |
| US8673920B2 (en) | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| ES2459468T3 (es) | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| JP5585822B2 (ja) * | 2010-05-11 | 2014-09-10 | 東レ・ファインケミカル株式会社 | 光学活性ニペコチン酸誘導体の製造方法 |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9000154B2 (en) | 2010-10-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2632465B1 (en) | 2010-10-27 | 2015-12-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012058134A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| US8703946B2 (en) | 2010-12-08 | 2014-04-22 | Vanderbilt University | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors |
| EP2651222A4 (en) * | 2010-12-17 | 2014-04-30 | Univ Vanderbilt | BICYCLIC TRIAZOL AND PYRAZOLLACTAME AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS |
| CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| US8865725B2 (en) | 2011-03-15 | 2014-10-21 | Vanderbilt University | Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| EA022019B1 (ru) | 2011-04-26 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Этинильные производные в качестве положительных аллостерических модуляторов mglur5 |
| MY165141A (en) | 2011-04-26 | 2018-02-28 | Hoffmann La Roche | Pyrazolidin-3-one derivatives |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| ES2605164T3 (es) | 2011-08-19 | 2017-03-13 | Merck Sharp & Dohme Corp. | Inhibidores del canal de potasio de la médula renal externa |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013039802A1 (en) | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| EP2771004B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771005B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9108947B2 (en) | 2011-10-31 | 2015-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
| EP2773199B1 (en) | 2011-10-31 | 2019-04-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9126988B2 (en) | 2011-12-13 | 2015-09-08 | Bial—Portela & Ca, S.A. | Intermediate for preparing a catechol-O-methyltransferase inhibitor |
| US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US20130345205A1 (en) * | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| US20130345204A1 (en) * | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| WO2014002051A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
| EP2867229B1 (en) | 2012-06-28 | 2017-07-26 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| CN104640855B (zh) | 2012-06-28 | 2017-08-29 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| CN104619698B (zh) | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| US9550755B2 (en) | 2012-07-12 | 2017-01-24 | Novartis Ag | Complement pathway modulators and uses thereof |
| SI2875000T1 (sl) | 2012-07-17 | 2017-01-31 | F.Hoffmann-La Roche Ag | Ariletinilni derivati |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| UA113223C2 (xx) | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| ES2594031T3 (es) | 2012-09-27 | 2016-12-15 | F. Hoffmann-La Roche Ag | Derivados de ariletinilo |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| WO2014085210A1 (en) | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014099633A2 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| US9765074B2 (en) | 2013-03-15 | 2017-09-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016065586A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Pyrazole, triazole and tetrazole orexin receptor antagonists |
| WO2016065584A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Piperidine oxadiazole and thiadiazole orexin receptor antagonists |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| AU2016273751B2 (en) | 2015-06-03 | 2020-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| TWI691486B (zh) | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| WO2017201468A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR101862765B1 (ko) | 2017-04-21 | 2018-05-30 | 한국화학연구원 | N-아릴사이클릭아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| AU2019285184B2 (en) | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
| WO2026072192A1 (en) | 2024-09-27 | 2026-04-02 | Alto Neuroscience, Inc. | Effective treatment of depression in patients having poor cognition or impaired learning and/or memory with a mglur5 positive allosteric modulator |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC598A1 (fr) | 1966-02-16 | 1967-03-21 | Mauvernay Roland Yves | Nouveaux composés chimiques et procédé pour leur préparation |
| MC641A1 (fr) | 1967-03-08 | 1967-12-05 | Mauvernay Roland Yves | Nouveaux composés chimiques et procédé pour leur préparation |
| US3509153A (en) | 1967-03-24 | 1970-04-28 | Miles Lab | 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles |
| GB9603755D0 (en) * | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| AU2001233044A1 (en) | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
| JP4522651B2 (ja) | 2001-03-13 | 2010-08-11 | シェーリング コーポレイション | 新規非イミダゾール化合物 |
| FR2834406A1 (fr) | 2001-12-28 | 2003-07-04 | Thomson Licensing Sa | Procede de mise a jour d'une liste de revocation de cles, d'appareils ou de modules non-conformes dans un systeme de diffusion securise de contenu |
| CN1691944A (zh) * | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的噁二唑 |
| AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2004014881A2 (en) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| AU2004226450A1 (en) | 2003-03-26 | 2004-10-14 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
| JP2006522128A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| SG149900A1 (en) * | 2004-02-18 | 2009-02-27 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006123255A2 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
-
2005
- 2005-05-18 GB GBGB0510139.9A patent/GB0510139D0/en not_active Ceased
-
2006
- 2006-05-17 CA CA002609513A patent/CA2609513A1/en not_active Abandoned
- 2006-05-17 NZ NZ564255A patent/NZ564255A/en not_active IP Right Cessation
- 2006-05-17 US US11/920,597 patent/US20100004284A1/en not_active Abandoned
- 2006-05-17 KR KR1020077029430A patent/KR20080017040A/ko not_active Ceased
- 2006-05-17 CN CN2006800251573A patent/CN101218231B/zh not_active Expired - Fee Related
- 2006-05-17 WO PCT/IB2006/001882 patent/WO2006129199A1/en not_active Ceased
- 2006-05-17 BR BRPI0610067-8A patent/BRPI0610067A2/pt not_active IP Right Cessation
- 2006-05-17 EP EP06779844A patent/EP1896464A1/en not_active Withdrawn
- 2006-05-17 JP JP2008511822A patent/JP2008540636A/ja active Pending
- 2006-05-17 AU AU2006253863A patent/AU2006253863A1/en not_active Abandoned
- 2006-05-17 EA EA200702471A patent/EA014904B1/ru not_active IP Right Cessation
- 2006-05-17 MX MX2007014400A patent/MX2007014400A/es unknown
- 2006-05-17 UA UAA200714056A patent/UA92914C2/ru unknown
-
2007
- 2007-11-06 IL IL187189A patent/IL187189A0/en unknown
- 2007-11-28 ZA ZA200710280A patent/ZA200710280B/xx unknown
- 2007-12-17 NO NO20076477A patent/NO20076477L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540637A5 (enExample) | ||
| JP2008540635A5 (enExample) | ||
| JP2008540634A5 (enExample) | ||
| CN1909907B (zh) | 喹啉衍生物及其在制备分枝杆菌抑制剂中的用途 | |
| EP1926719B1 (en) | 2-aniline-4-aryl substituted thiazole derivatives | |
| TW591022B (en) | Tetrahydropyridino or piperidino heterocyclic derivatives | |
| CN102439015B (zh) | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 | |
| JP5081617B2 (ja) | 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用 | |
| JP2004536066A5 (enExample) | ||
| CN101218231B (zh) | 作为代谢型谷氨酸受体的正变构调节剂的杂环化合物 | |
| JP5932779B2 (ja) | シグマ受容体阻害剤としてのピラゾール化合物 | |
| TW200817394A (en) | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | |
| CN101218232B (zh) | 噁二唑衍生物和它们作为代谢型谷氨酸受体的正变构调节剂的用途 | |
| AU2015357167B2 (en) | 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | |
| RU2011129786A (ru) | Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний | |
| JP2012526737A (ja) | １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 | |
| JP2017510576A5 (enExample) | ||
| JP2005510473A5 (enExample) | ||
| RS20050058A (sr) | Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora | |
| AU2015295301B2 (en) | 6,7-dihydropyrazolo[1,5-alpha]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | |
| JP2007519687A (ja) | マイコバクテリア抑制剤としての使用のためのキノリン誘導体 | |
| JP2019537592A5 (enExample) | ||
| JP2004002478A (ja) | 鎮痙薬活性を有するベンゾ−およびピリドピラン誘導体 | |
| JP2019537581A5 (enExample) | ||
| JP2007520539A5 (enExample) |